網站內容顯示
2017 was a productive year at Galyatech! And we're hoping to make much more progress in 2018! Read more below!
A Look Back on 2017
In 2017, we:
Studies
- performed 3 in vitro preclinical tests in cells
- designed 3 in vivo preclinical animal model studies (plus 2 additional supplementary studies)
- initiated 1 in vivo preclinical study in mice (and another study coming soon)
Animal Model Colonies
- established 1 Npc1 mouse colony (with an existing mouse model)
- worked closely with 1 existing NPC1 cat colony
Manufacturing
- manufactured more than 10 preparations of non-pathogenic AAV9 virus
- experimented with more than 3 different variations of the virus components
Legal
- entered more than 10 new legal agreements, including:
- 1 new research collaboration agreement with a major scientific research institution and
- 6 agreements with organizations and consultants in areas of manufacturing, animal models, and process development
Project Management
- participated in 100's of phone and/or teleconference calls
- sent and received around 4,000 emails
- received great advice from our 3 scientific advisory board (SAB) members: Brittney Gurda, Cristin Davidson and Steven Gray
Conferences
- were in-person at 5 conferences/symposiums focused on gene therapy and/or rare disease:
- WORLD Symposium (Feb 2017)
- NYAS: Gene Therapy for Rare Diseases Conference (Apr 2017)
- Hanson Wade: Gene Therapy for Rare Disorders (Apr 2017)
- Michael, Marcia, and Christa Parseghian Scientific Conference for Niemann-Pick Type C Research (June 2017)
- Global Genes 2017 RARE Patient Advocacy Summit (Sep 2017)
Next Update
We hope to share more details with you soon in the next update!
Map.